Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADPT 
Adaptive Biotechnologies Corp (ADPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: ADPT (4-star) is a STRONG-BUY. BUY since 3 days. Simulated Profits (-4.46%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.57
1 Year Target Price $19.57
| 3 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.89% | Avg. Invested days 31 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.88B USD | Price to earnings Ratio - | 1Y Target Price 19.57 |
Price to earnings Ratio - | 1Y Target Price 19.57 | ||
Volume (30-day avg) 8 | Beta 2.22 | 52 Weeks Range 5.80 - 20.76 | Updated Date 12/2/2025 |
52 Weeks Range 5.80 - 20.76 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When After Market | Estimate -0.18 | Actual 0.06 |
Profitability
Profit Margin -31.5% | Operating Margin (TTM) 10.95% |
Management Effectiveness
Return on Assets (TTM) -9.32% | Return on Equity (TTM) -37.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2870431596 | Price to Sales(TTM) 11.38 |
Enterprise Value 2870431596 | Price to Sales(TTM) 11.38 | ||
Enterprise Value to Revenue 11.36 | Enterprise Value to EBITDA -1 | Shares Outstanding 152665188 | Shares Floating 117659060 |
Shares Outstanding 152665188 | Shares Floating 117659060 | ||
Percent Insiders 2.27 | Percent Institutions 97.01 |
Upturn AI SWOT
Adaptive Biotechnologies Corp
Company Overview
History and Background
Adaptive Biotechnologies Corp. was founded in 2009. It leverages sequencing technology to profile and decode the adaptive immune system. The company's initial focus was on research, but it has since expanded into clinical diagnostics and therapeutics.
Core Business Areas
- Minimal Residual Disease (MRD): ClonoSEQ is a suite of diagnostic tests to detect and monitor MRD in patients with B-cell and T-cell malignancies.
- Immune Medicine: Developing therapies and diagnostics based on the understanding of the adaptive immune system, including cellular therapies.
- Drug Discovery: Using its immune profiling platform to identify novel drug targets and develop therapeutics.
Leadership and Structure
The leadership team includes notable figures in biotechnology. The organizational structure is typical for a biotechnology company, with research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- ClonoSEQ: A FDA-cleared assay for detecting and monitoring minimal residual disease (MRD) in blood cancer patients. No specific market share is available but has increasing presence. Competitors include Invivoscribe, Labcorp and Quest Diagnostics.
- T-Detect: A test to detect past or present infections by analyzing T-cell responses. Competitors include Quanterix.
Market Dynamics
Industry Overview
The industry is characterized by rapid innovation in genomics, diagnostics, and immunotherapies. Precision medicine and personalized healthcare are key drivers.
Positioning
Adaptive Biotechnologies is positioned as a leader in immune-driven medicine, with a proprietary platform for understanding and leveraging the adaptive immune system.
Total Addressable Market (TAM)
The TAM for immune-driven medicine is estimated to be in the billions of dollars. Adaptive is positioned with advanced tech to capture a significant share through diagnostic and therapeutic offerings.
Upturn SWOT Analysis
Strengths
- Proprietary immune profiling platform
- Strong partnerships with pharmaceutical companies
- FDA-cleared diagnostic tests
- Deep expertise in immunology and genomics
Weaknesses
- Reliance on partnerships
- High operating expenses
- Negative profitability
- Complex regulatory environment
Opportunities
- Expanding applications of immune profiling
- Developing novel immunotherapies
- Strategic acquisitions
- Increased adoption of MRD testing
Threats
- Competition from other genomics companies
- Changes in reimbursement policies
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- ILMN
- QTRX
- DGX
- LH
Competitive Landscape
Adaptive Biotechnologies competes with companies in genomics, diagnostics, and immunotherapies. Its key advantage is its proprietary immune profiling platform. Disadvantages are high costs and partnership reliance.
Growth Trajectory and Initiatives
Historical Growth: Growth has been fueled by increasing adoption of ClonoSEQ and partnerships with pharmaceutical companies.
Future Projections: Future growth depends on the successful commercialization of new products and continued expansion of ClonoSEQ. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expansion of T-Detect, partnering on drug development programs, and improving operating efficiency.
Summary
Adaptive Biotechnologies is a company with strong intellectual property in the adaptive immune system space. While possessing a unique tech platform, the company struggles with profitability, relying on partnerships. Future success requires the commercialization of new products and effective cost management. Competition and regulatory changes also require careful monitoring.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adaptive Biotechnologies Corp
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Chairman Mr. Chad M. Robins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 619 | Website https://www.adaptivebiotech.com |
Full time employees 619 | Website https://www.adaptivebiotech.com | ||
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.